Get the Stockscreener App
1.76
1.15%
0.02
After Hours:
1.77
0.01
+0.57%
Mereo Biopharma Group Plc Adr stock is traded at $1.76, with a volume of 1.36M.
It is up +1.15% in the last 24 hours and down -36.92% over the past month.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
See More
Previous Close:
$1.74
Open:
$1.75
24h Volume:
1.36M
Relative Volume:
0.64
Market Cap:
$279.84M
Revenue:
$10.00M
Net Income/Loss:
$-29.47M
P/E Ratio:
-8.80
EPS:
-0.2
Net Cash Flow:
$-21.55M
1W Performance:
-0.56%
1M Performance:
-36.92%
6M Performance:
-39.52%
1Y Performance:
-56.86%
1-Day Range:
$1.71
$1.80
1-Week Range:
$1.65
$1.885
52-Week Range:
$1.57
$5.02
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Name
Mereo Biopharma Group Plc Adr
Sector
Industry
Phone
4403330237300
Address
ONE CAVENDISH PLACE, LONDON
Compare MREO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
1.76 | 276.66M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-25 | Initiated | JP Morgan | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-13-23 | Resumed | BTIG Research | Buy |
| Aug-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-05-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Needham | Buy |
View All
Mereo Biopharma Group Plc Adr Stock (MREO) Latest News
Investors in Mereo BioPharma Group plc (MREO) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.
MREO ACTIVE INVESTIGATION: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky Now - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - PR Newswire
ATTENTION MREO Shareholders: Lost Money on Mereo BioPharma Group plc? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Investigation Opened on Behalf of Mereo BioPharma Group plc (MREO) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Ongoing Securities Investigation into Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Mereo BioPharma Group plc (MREO) And Encourages Stockholders to Connect - ACCESS Newswire
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Consensus Rating of “Buy” by Brokerages - Defense World
Investigation Underway: Mereo BioPharma Group plc (MREO)Contact Levi & Korsinsky Over Securities Law Violations - ACCESS Newswire
Mereo BioPharma Group plc (MREO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
MREO ALERT: Ongoing Investigation Into Mereo BioPharma Group plcContact Levi & Korsinsky - ACCESS Newswire
Protect Your Investment: Contact Levi & Korsinsky About the Mereo BioPharma Group plc (MREO) Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Mereo BioPharma Group plc (MREO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
BTIG reiterates Buy rating on Mereo BioPharma stock amid trial progress By Investing.com - Investing.com South Africa
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 0.43% - Investing.com India
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End - Yahoo Finance
JPMorgan maintains Mereo BioPharma stock rating despite trial setback By Investing.com - Investing.com India
JPMorgan maintains Mereo BioPharma stock rating despite trial setback - Investing.com
Mereo BioPharma and Ultragenyx advance Phase 3 Orbit study for osteogenesis imperfecta - Investing.com India
SEC Form N-CSRS filed by abrdn World Healthcare Fund Shares of Beneficial Interest - Quantisnow
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail
Mereo BioPharma Group plc SEC 10-Q Report - TradingView
Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewswire
Mereo Biopharma Group Plc ADR (MREO) can make a big difference with a little luck - Sete News
Analyzing Mereo Biopharma Group Plc ADR (MREO) After Recent Trading Activity - knoxdaily.com
How should investors view Mereo Biopharma Group Plc ADR (MREO)? - uspostnews.com
Analytical Overview: Mereo Biopharma Group Plc ADR (MREO)’s Ratios Tell a Financial Story - DWinneX
Balance Sheet Insights: Halliburton Co (HAL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
INN’s latest rating updates from top analysts. - knoxdaily.com
EVLV’s 2023 Market Dance: Down -10.63% – Time to Invest? - investchronicle.com
Mereo Biopharma Group Plc ADR: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - investchronicle.com
Mereo Biopharma Group Plc ADR [MREO] Shares Fall -0.78 % on Thursday - knoxdaily.com
Brookdale Senior Living Inc [BKD] Records 50-Day SMA of $5.84 - knoxdaily.com
VST Stock Sees Surge of Approximately 7.21% in Last Five Days - knoxdaily.com
Core & Main Inc [NYSE: CNM] Sees Increase in Stock Value - knoxdaily.com
This trade activity should not be overlooked: Mereo Biopharma Group Plc ADR (MREO) - Sete News
Financial Metrics Check: B. Riley Financial Inc (RILY)’s Ratios for Trailing Twelve Months - DWinneX
Mereo Biopharma Group Plc ADR [MREO] Investment Appeal on the Rise - knoxdaily.com
Freeport-McMoRan Inc [FCX] Stock sold by Insider Robertson Maree E. for $0.58 million - knoxdaily.com
D.R. Horton Inc (DHI) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Insider Sale Alert: Genworth Financial Inc [GNW] – Is it Time to sell? - knoxdaily.com
Mereo Biopharma Group Plc ADR (MREO) requires closer examination - uspostnews.com
SMX (Security Matters) Plc (SMX) shows promising results - uspostnews.com
Should investors be concerned about Uranium Energy Corp (UEC)? - uspostnews.com
Is Aquestive Therapeutics Inc (AQST) worth investing in despite its overvalued state? - uspostnews.com
Mereo Biopharma Group Plc Adr Stock (MREO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):